Autoantibody Profiles of Myasthenia Gravis, Thymoma & Lambert-Eaton Myasthenic Syndrome

Serum AChR Modulating Antibody Values and Interpretation

July 2009

Results from the modulating assay should be interpreted as follows: for patients who do not have myasthenia gravis, one can detect 0% to 20% loss of the acetylcholine receptor. Patients with myasthenia gravis, you see >30% loss, and the amount of loss is generally proportional to clinical severity. In patients who have myasthenia gravis with thymoma, the loss of acetylcholine receptor is usually >90%. In patients with Lambert-Eaton syndrome, >30% loss can be encountered in 5% to 10% of patients. All of these antibody values will be lower in immunosuppressed patients.

< Previous Slide

Antibody Values and Interpretation

Next Slide >

 

Jump to section:

• Introduction
• Serological Diagnostic Algorithms
• 'Hot Topic' Points
• What are MG and LES?
• What are MG and LES?
• MG: Clinical Diagnosis
• MG: Neoplastic Accompaniments
• LES: Clinical Diagnosis
• LES: Electromyography (EMG) Findings
• LES: Neoplastic Accompaniments
• Autoantibodies Aiding MG Diagnosis
• Autoantibodies Aiding MG Diagnosis
• Single Assay Detects AChR Modulating and AChR Blocking Antibodies
• Serum AChR Modulating Antibody Values and Interpretation
• Reasons to Discontinue Testing for AChR Blocking Antibody
• Striational Antibodies
• Autoantibodies Detected in MG Patients with Thymoma
• Autoantibodies Aiding the Diagnosis of LES
• Autoantibodies Aiding the Diagnosis of LES
• Myasthenia Gravis: Adult Diagnostic Algorithm
• Myasthenia Gravis: Pediatric Diagnostic Algorithm
• Myasthenia Gravis: Thymoma Diagnostic Algorithm
• Myasthenia Gravis/Lambert Eaton Syndrome Diagnostic Algorithm
• Summary
• Questions?